Evidence map›Paper›PMID 41090158›Full record

ArticleBlood neoplasia2025

Orally available decitabine prodrug OR-2100 induces mitotic perturbation for the treatment of double-hit lymphoma.

Keisuke Kidoguchi, Hiroshi Ureshino, Yuta Yamamoto, Ryo Yanagiya, Yuki Kurahashi, Yuki Fukuda-Kurahasi, Yumeka Mine, Shigehisa Aoki, Kazutaka Nakashima, Hiroaki Miyoshi and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Blood neoplasia, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Keisuke KidoguchiDivision of Hematology, Respiratory Medicine, and Oncology, Department of Internal Medicine, Faculty of Medicine, Saga University, Saga, Japan.
Hiroshi UreshinoDivision of Hematology, Respiratory Medicine, and Oncology, Department of Internal Medicine, Faculty of Medicine, Saga University, Saga, Japan.
Yuta YamamotoDivision of Hematology, Respiratory Medicine, and Oncology, Department of Internal Medicine, Faculty of Medicine, Saga University, Saga, Japan.
Ryo YanagiyaDivision of Hematology, Respiratory Medicine, and Oncology, Department of Internal Medicine, Faculty of Medicine, Saga University, Saga, Japan.
Yuki KurahashiDepartment of Drug Discovery and Biomedical Sciences, Faculty of Medicine, Saga University, Saga, Japan.
Yuki Fukuda-KurahasiDepartment of Drug Discovery and Biomedical Sciences, Faculty of Medicine, Saga University, Saga, Japan.
Yumeka MineDepartment of Pathology and Microbiology, Faculty of Medicine, Saga University, Saga, Japan.
Shigehisa AokiDepartment of Pathology and Microbiology, Faculty of Medicine, Saga University, Saga, Japan.
Kazutaka NakashimaDepartment of Pathology, Kurume University School of Medicine, Kurume, Japan.
Hiroaki MiyoshiDepartment of Pathology, Kurume University School of Medicine, Kurume, Japan.
Koichi OhshimaDepartment of Pathology, Kurume University School of Medicine, Kurume, Japan.
Atsushi KawaguchiEducation and Research Center for Community Medicine, Faculty of Medicine, Saga University, Saga, Japan.
Shinya KimuraDivision of Hematology, Respiratory Medicine, and Oncology, Department of Internal Medicine, Faculty of Medicine, Saga University, Saga, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Double-hit lymphoma (DHL), an aggressive B-cell lymphoma with a poor prognosis, harbors rearrangements of

Identifiers

PMID41090158
PMCPMC12517088

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.